Biosyngen Pte Ltd
About This Business
G iving P atients the B est C hance to S urvive
Biosyngen is a Global Leader in Cell Therapy.
We design cutting-edge immunotherapies aiming to provide patients the best treatment option.
LEARN MORE
LEARN MORE
LEARN MORE
Pipelines consisting of 3 proven technologies in CGT (CAR-T, TCR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more
No approved cell immunotherapy for solid tumor to date
Currently, more than half of clinical trials are focusing on blood cancer. However, the larger unmet need and challenge is Solid Tumor.
90% of all cancer patients with solid tumors
According to the global cancer data of 2021, more than 90% of newly cancer cases worldwide are solid tumor patients, significantly outnumbering patients with blood cancers.
Developing cutting-edge immunotherapies to address unmet needs in oncology
Developing first-in-class (FIC) product against solid tumors
Products in the pipeline are first-in-class (FIC) against solid tumors, focusing on unmet needs globally, well positioned to fill the gap in the market.
Pipelines consisting of 3 proven technologies in CGT (CAR-T, TCR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more
* Biosyngen's Differentiation · Next generation design enhancing the persistence of T cells in vivo
· High affinity/avidity/specificity against tumor specific antigen
* Biosyngen's Pipeline · BRL03: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.
* Biosyngen's Differentiation · Able to be cryopreserved to address long distance transportation issue
· Does not require high dose IL-2 infusion
* Biosyngen's Pipeline · BST02: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.
* Biosyngen's Differentiation · In-human data showing clinical efficacy
· Unique target/FIC
· Enhanced safety profile
* Biosyngen's Pipeline · BRG01: Ongoing Phase II clinical trials in China/U.S.
· BGT007: Dual CAR-T, IIT in progress
· ALLO-CEL: In-human by 2024
Established proprietary technology platforms for R&D translation &
immunotherapy drug development against solid tumors
Automated and intelligent cell manufacturing platform
Automated and intelligent cell manufacturing platform
· Improved production cycle time of CAR-T/TCR-T product to 10-days.
·Manufactured in GMP facility in compliance to FDA and CDE requirements. LEARN MORE
T cell safety optimization platform
T cell safety optimization platform
· Unique T cell signaling tweaking strategy and TME-specific promoter to broaden tumor cell coverage while ensuring safety. LEARN MORE
T cell functional enhancement platform
T cell functional enhancement platform
· Library consisting of hundreds of motifs for T cell functional enhancement. LEARN MORE
Antigen/Antibody/TCR discovery platform
Antigen/Antibody/TCR discovery platform
· Large tumor-specific TCR library for multiple high-frequency HLA haplotypes.
· Fast screening / optimization. LEARN MORE
Global strategy to serve patients worldwide with scalable GMP
production capability and broad clinical network
* America Stanford University School of Medicine
* France Gustave Roussy Cancer Campus
* Germany Helmholtz Zentrum München-German Research Center
* China Sun Yat-sen University Cancer Center
* Singapore The Agency for Science, Technology and Research, Singapore
* Australia QIMR Berghofer Medical Research Institute
Exclusive Partnership with Public Agencies to pursue breakthrough in development
Accelerate R&D progress with cooperative of Top scientific research institutions
* Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.
Collaboration targets multiple indications . exclusive collaboration in NPC.
13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government
Abundant clinical resources around the world
* Clinical trials have been initiated at 8 medical centers in China
* Clinical trials of NCCS are already ongoing in Singapore
Dual site strategy
Dual site strategy with dual R&D and GMP Facilities to address Global needs
China ｜ The largest GMP Facility in South China
Singapore ｜ Largest private GMP Facility in Singapore
China ｜ The largest GMP Facility in South China
Singapore ｜ Largest private GMP Facility in Singapore
China ｜ The largest GMP Facility in South China
Latest Headlines
LEARN MORE
PM Lee receives a first-hand update by Biosyngen on its progress in cell therapy 2023-03-29